港股異動 | 新冠治療概念股連續走強 國家藥監局近日批准輝瑞新冠口服藥進口註冊
格隆匯2月18日丨新冠治療概念股連續走強,港股市場騰盛博藥漲逾6%,開拓藥業漲4.77%,君實生物漲3.59%;A股市場雅本化學和翰宇藥業漲停。2月12日,國家藥監局網站公吿,按照藥品特別審批程序,進行應急審評審批,附條件批准輝瑞公司新冠病毒治療藥物奈瑪特韋片/利托那韋片組合包裝(即Paxlovid)進口註冊,用於治療成人伴有進展為重症高風險因素的輕至中度新型冠狀病毒肺炎(COVID-19)患者。在疫情常態化大背景之下,各類治療新冠的藥物被寄予厚望。其中,口服小分子化學藥憑藉給藥便捷、成本低廉等優勢備受市場關注,國內外也隨即湧現出一批新冠口服藥藥企,據不完全統計,目前全球在研的新冠口服藥約有15款。中國企業中,前沿生物、眾生睿創、先聲藥業、雲頂新耀、歌禮制藥、廣生中霖、藥明康德的在研新冠口服藥處在臨牀前階段,開拓藥業、真實生物、君實生物已經進行到了臨牀試驗階段。進展最快的是君實生物研發的VV116和開拓藥業研發的普克魯胺。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.